参七合剂治疗非酒精性脂肪性肝病的临床疗效

发布时间：2018-06-04 06:14

本文选题：非酒精性脂肪性肝病 + 参七合剂　；参考：《实用医学杂志》2015年02期

【摘要】：目的:观察参七合剂对非酒精性脂肪性肝病(NAFLD)患者氨基转移酶水平、血脂水平及肝脏超声学指标的影响,评价其临床疗效。方法:将50例NAFLD患者随机分成易善复组(给予易善复1.368 g/d)参七合剂组(给予参七合剂20 g/d),每组25例,疗程为2个月。治疗前后分别进行血脂4项、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)和肝脏超声学指标检测。采用自动生化分析仪,按照试剂盒要求检测ALT、AST及血脂4项。使用西门子Sequia512超声诊断仪检测肝脏超声学指标。结果:ALT、AST、血脂4项及肝脏超声学指标结果显示,参七合剂和易善复均能降低ALT、AST、TC、TG、LDL-C(P0.01,P0.05),升高HDL-C(P0.01,P0.05),减轻肝细胞脂肪变性程度。与易善复比较,参七合剂降低ALT、AST、TC、TG、LDL-C(P0.01),升高HDL-C(P0.01),减轻肝细胞脂肪变性,差异有显著性。结论 :参七合剂对NAFLD有较好的疗效。
[Abstract]:Aim: to observe the effects of Shenqi mixture on the levels of aminotransferase, blood lipid and liver ultrasound in patients with NAF LDD. Methods: fifty patients with NAFLD were randomly divided into two groups: Yi Shanfu group (1.368 g / d) Shenqi mixture group (20 g / d) group (25 cases in each group). The course of treatment was 2 months. Serum lipids, alanine aminotransferase (alt), aspartate aminotransferase (AST) and liver ultrasound were measured before and after treatment. Four items of alt AST and blood lipids were detected by automatic biochemical analyzer according to the requirements of kit. The ultrasonic parameters of liver were detected by Siemens Sequia512 ultrasonic diagnostic instrument. Results the results showed that Shenqi mixture and Yi Shanfu could decrease the level of LDL-CU, increase the level of HDL-CU P0.01 and decrease the degree of steatosis of hepatocytes. Compared with Yi Shanfu, Shenqi mixture decreased the level of ALT ASTN TGN LDL-CU P0.01, increased HDL-CU P0.01, and alleviated hepatocyte steatosis, the difference was significant. Conclusion: Shenqi mixture has better curative effect on NAFLD.
【作者单位】：常德职业技术学院内科教研室;常德职业技术学院第二附属医院;
【基金】：湖南省教育厅科技计划项目(编号:12C0969) 常德市科技局科技计划项目(编号:2010BS02)
【分类号】：R575.5

【参考文献】